Ron Adams is the Chief Technology Officer for Freyja Healthcare, Origyn and Polygon Medical and past President of Emmy Medical . After completing Bachler’s and Master’s degrees in Mechanical  Engineering at Virginia Tech. Ron joined J&J Ethicon Endosurgery in 1992 developing new technologies necessary to transition open surgical procedures to laparoscopic approaches. Ron joined Boston  Scientific in 1995 leading efforts to develop endoluminal procedures. In 2002, Ron joined Smith &  Nephew Endoscopy where he launched the TruClear hysteroscopic morcellation system. Later, Ron co-founded Interlace Medical that brought the Myosure system to the market. Ron is currently leading the  technology development efforts at Frejya Healthcare developing a number of innovative medical devices in conjunction with Freya CMO, Jon Einarsson, MD.

Rachel Blank is the founder and CEO of Allara , a virtual care platform built for the millions of women living with complex, chronic conditions like PCOS and Endometriosis. Allara makes expert healthcare accessible nationwide by connecting patients with highly trained specialists, including ob-gyns, endocrinologists, and dietitians, who treat patients from a whole health perspective. Rachel founded Allara following her own experience struggling to get a diagnosis and trusted treatment for PCOS. Prior to founding Allara, Rachel was the Director of Strategy at Ro and is a graduate of Harvard Business School.

Beatrice Chemla, with a dual background in pharmacy and business (PharmD & MBA), began her career in the pharmaceutical industry at major corporations such as UCB and Sanofi. At Sanofi, she led the launch of generic drugs in France, a highly disruptive and pioneering approach to rethinking access to healthcare at the time. As Marketing Director for Sanofi’s Generic Drugs Division, she shaped strategy in a fast-evolving market.
Driven by a desire to further immerse herself in the healthcare ecosystem, Beatrice transitioned to the consulting industry. She joined Stethos as a Senior Partner, leading strategic healthcare market studies. Later, she founded Listening Pharma, a boutique healthcare consultancy that achieved a $1M turnover and was successfully acquired by UK-based agency SPA Future Thinking. Beatrice continued there as Head of Health Services, overseeing global research and strategy.

Her years of close collaboration with diverse healthcare stakeholders—from regulators to patients—deepened her conviction to solve health challenges in practical and impactful ways.

After relocating to Israel, a global hub for healthcare innovation, Beatrice served as a Partner at Cukierman Life Sciences. She then pursued an MBA in Healthcare Innovation at Reichman University in collaboration with Sheba Tel Hashomer Hospital. This period marked a turning point, during which she connected with co-founders, built a robust entrepreneurial ecosystem, and co-founded IMMA, where she currently serves as CEO. IMMA is reshaping fertility care with a science-driven, patient-centered approach.

In 2022, Beatrice was selected to join the McKinsey First Circle of Female Founders, a recognition of high-potential women entrepreneurs shaping the future of healthcare.

As a side note, her PharmD thesis focused on the cellular toxicity of asbestos at INSERM, an early sign of her enduring passion for cell biology—now rekindled through IMMA’s ambition to advance oocyte quality and its role in the IVF process.

Natalie Crawford, MD is board certified in both Obstetrics and Gynecology and Reproductive Endocrinology and Infertility and is co-founder of Fora Fertility, a boutique fertility practice in Austin, Texas. Dr. Crawford is CEO and co-founder of Pinnacle, a professional network for women in medicine focused on leadership and education. Dr. Crawford completed her undergraduate education at Auburn University obtaining a degree in Nutrition Science, Medical School at University of Texas Medical Branch, Residency in Obstetrics and Gynecology at University of Texas Southwestern, and Fellowship in Reproductive Endocrinology and Infertility at the University of North Carolina, concurrently obtaining a Master of Science in Clinical Research. She is an Affiliate Clinical Professor of Women’s Health at the University of Texas Dell Medical School. Dr. Crawford is a digital health educator on fertility and reproductive health on Instagram/TikTok @nataliecrawfordmd, twitter @ncrawfordmd, and You Tube “Natalie Crawford, MD,” and she is the host of the popular podcast “As a Woman: Fertility, Hormones and Beyond” with over 5 million downloads. Her debut book, “The Fertility Formula”, will be released by Penguin Random House.

Dr. Vrunda B. Desai is a physician-scientist and healthcare executive with a distinguished career at the intersection of academic medicine, clinical innovation, and industry strategy. Board certified in Obstetrics and Gynecology with fellowship training in minimally invasive robotic gynecologic surgery, Dr. Desai brings a unique blend of clinical expertise and strategic leadership to her work in advancing women’s health.

As Vice President of Medical Affairs and Clinical Strategy, Dr. Desai leads cross-functional initiatives that integrate scientific evidence, clinical insights, and market intelligence to drive innovation in women’s health solutions. Her work spans product development, evidence generation, clinical strategy, and stakeholder engagement across the healthcare ecosystem.

Dr. Desai holds an academic appointment as Associate Professor Adjunct at Yale School of Medicine, where she co-directs a multidisciplinary course and mentors trainees in clinical research and health policy. Her research portfolio focuses on healthcare economics, clinical outcomes, and value-based care in gynecology. She collaborates with a cross-institutional team at Yale, Columbia University Vagelos College of Physicians and Surgeons, and Johns Hopkins School of Medicine, contributing to high-impact publications and national discourse on optimizing care delivery.

As US Fertility’s Medical Director and Chief Research Officer, Kate Devine, M.D. leads USF’s dedicated Research Division in expanding the knowledge base of our field on behalf of patients everywhere striving to achieve their dreams of family. Dr. Devine supports the faculty of the six USF-affiliated Reproductive Endocrinology and Infertility fellowships. Furthermore, she oversees a culture of excellence in the medical care of our patients across the USF Network.

Dr. Devine, a board-certified Reproductive Endocrinologist, cares for patients in Washington, D.C., and has served as Research Director at Shady Grove Fertility for nearly a decade. She is Clinical Professor of Obstetrics and Gynecology at George Washington University and Associate Program Director for the Reproductive Endocrinology and Infertility Fellowship at the National Institutes of Health (NIH). Dr. Devine serves as Chair of the Society for Reproductive Endocrinology and Infertility (SREI) Research Committee, Chair of the Society for Assisted Reproductive Technology (SART) Quality Assurance Committee, and on the Editorial Board of Fertility and Sterility. She has authored more than 70 peer-reviewed publications, has received numerous research grants and awards, including the 2023 ASRM New Investigator Award, and has spoken nationally and internationally on the topic of her research, which focuses primarily on endometrial receptivity and optimization of frozen embryo transfer protocols. She earned her BA from Columbia University and MD from Albert Einstein College of Medicine. She completed residency at New York University Medical Center and fellowship at the NIH.

Dr. Amy Divaraniya is the Founder and CEO of Oova, a groundbreaking women’s health company redefining how hormone health is measured and managed. With a decade of experience as a data scientist specializing in genomics and biomarker discovery, she brings a rare blend of scientific expertise and personal mission to her work. After facing her own fertility challenges, Dr. Divaraniya left her career in precision medicine to create the solution she wished existed.

That solution became Oova: the first at-home test to measure multiple hormones through urine and deliver real-time, clinically backed insights into fertility and perimenopause. Today, Oova is trusted by over 300 clinics and hospitals across the U.S. and is helping thousands of women gain clarity and control over their hormonal health.

Dr. Divaraniya has been recognized as one of Crain’s New York Business’ Notable Leaders in Healthcare and is a leading voice at the intersection of diagnostics, technology, and women’s health. Her work has been featured in The New York Times, The Washington Post, Forbes, CBS News, and Business Insider.

Anuja Dokras, MD, MHCI, PhD is the Executive Director of the Women’s Health Center for Clinical Innovation (WHCCI) and the Founder’s Professor of Women’s Health in the Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility at the University of Pennsylvania, Philadelphia. WHCCI offers a cross disciplinary culture of innovation to achieve seamless, high-value healthcare delivery throughout a woman’s lifespan. Dr Dokras oversees ~20 programs supported by federal funds, payers and industry that focus on redesigning and reimagining health care delivery across the breadth of women’s health. Leveraging digital health technologies, novel care model designs and AI, the Center has scaled several programs and published their findings. Dr Dokras is also the Director of the PENN Polycystic Ovary Syndrome (PCOS) Center, a multi-disciplinary center providing care across the lifespan. Dr. Dokras brings to this role her extensive research experience in translational medicine and clinical trials with a focus on understanding cardiometabolic risk and mental health co-morbidities associated with PCOS. Dr. Dokras is an internationally recognized NIH-funded researcher, global patient advocate and educator. She was the past President and is the current Executive Director of the international Androgen Excess (AE)-PCOS society. She is on the senior editorial team of Endocrine Reviews and Fertility & Sterility and is co-editor of the textbook Yen and Jaffe’s Reproductive Endocrinology. She received her training in obstetrics, gynecology and reproductive endocrinology at Yale New Haven Hospital, a master’s in Healthcare Innovation (MHCI) from the University of Pennsylvania, and a Doctor of Philosophy from the University of Oxford.

Eduardo Hariton, MD, MBA is a double board-certified OB/GYN and Reproductive Endocrinologist who practices at the Reproductive Science Center of the San Francisco Bay Area. In addition to his clinical work, Dr. Hariton serves as Vice President of Strategic Initiatives at US Fertility, the largest partnership of fertility practices in the United States. In this role, he leads efforts around innovation strategy, investment partnerships, and clinical innovation across the network.

Dr. Hariton is also the Managing Director of the USF Innovation Fund, a venture fund focused on investing in early-stage companies that are transforming reproductive health. He works closely with founders, operators, and investors to bring impactful technologies and care models into practice, helping to advance patient outcomes and improve the experience of fertility care.

He has authored over 70 peer-reviewed publications and frequently speaks on topics at the intersection of reproductive medicine, business, and technology, including the application of AI, automation, and decision support tools in fertility workflows. Dr. Hariton earned his MD from Harvard Medical School and his MBA from Harvard Business School. He completed his residency at Brigham and Women’s Hospital and Massachusetts General Hospital and his fellowship in reproductive endocrinology and infertility at UCSF.

Dr. Hariton is passionate about building the future of reproductive care through thoughtful innovation, scalable solutions, and patient-centered design.

Dr Hotaling is a Professor of Surgery(Urology), Associate Vice President of Research for  Innovation for the University of Utah , Director of Men’s Health and co-director of the DELPHI initiative at The University of Utah School of Medicine.  Dr. Hotaling has founded four companies related to men’s health, one of which has an FDA approved product on the market, holds multiple patents, has over 270 publications and has had over $13M in NIH grants related to male infertility, sexual medicine and BPH.  He has expertise in scRNA sequencing, the impacts of male infertility on somatic health, genetics of ED and innovation in men’s health and infertility.  He is also an Associate Editor of Fertility & Sterility and was the president of the Society for the Study of Male Reproduction (SSMR), the pre-eminent US male infertility society in 2022.

Priyanka Jain is the co-founder & CEO of Evvy, a precision medicine company leveraging the vaginal microbiome to improve women’s health outcomes. Evvy serves over 70,000 patients, 2,000 medical practitioners, and has built the world’s largest dataset on the vaginal microbiome — unlocking opportunities to better diagnose and treat infertility, preterm birth, gynecological cancers, and more.

Priyanka serves on advisory boards for the XPRIZE Foundation and the United Nations Foundation’s Girl Up campaign. She received her B.S. from Stanford University and has been recognized as Forbes 30 under 30, Inc’s Top Female Founders, and Goldman Sachs’ Most Exceptional Entrepreneurs.

Kathy Lee-Sepsick is the founder of Femasys, established in February 2004. She brings nearly three decades of leadership in the medical technologies industry, with a proven track record in scaling emerging companies and operating divisions. Ms. Lee-Sepsick holds over 200 global patents for Femasys’ products and candidates.

Previously, she held strategic, operational, and executive roles across various company life cycles, including at Novoste Corporation (intravascular therapy) and SaluMedica (biomaterials for artificial cartilage). Early in her career, she managed product strategy at Terumo Medical Corporation, collaborating closely with Boston Scientific.

Ms. Lee-Sepsick earned a BS in Biochemistry and an MBA from Rutgers University.

Dr. Brian Levine is a highly accomplished and recognized leader in reproductive medicine. A two-time founder and award-winning double-board-certified reproductive endocrinologist and obstetrician/gynecologist, Dr. Levine combines academic excellence with hands-on expertise to redefine fertility care.

He holds a B.S. from Cornell University, an M.S. and M.D. from New York University, and completed his residency at Columbia University Medical Center, followed by a fellowship at Weill Cornell Medical College.

Dr. Levine serves as the founding partner and practice director of CCRM New York, widely regarded as one of America’s top fertility clinics, where he has helped countless families on their path to parenthood. He is also the founder of Nodal, the premier online gestational surrogacy platform, which has revolutionized the surrogacy process by connecting intended parents and surrogates in a trusted and transparent way.

Mike MacKinnon is a seasoned healthcare executive with over 20 years of experience building and leading high-performance teams in the development and commercialization of innovative, complex medical devices.

He is currently the CEO of Freyja Healthcare, a Boston-based company transforming women’s health through minimally invasive technologies. Prior to Freyja, Mike served as CEO of Saranas, a pioneer in active bleed monitoring systems, which was acquired by Abiomed in July 2024.

Before that, he was a Partner and President at Madison Ventures +, a boutique private equity firm based in Greenwood Village, Colorado. Mike also served as CEO of Zidan Medical, an early-stage company focused on endobronchial ablation for early-stage lung cancer, and as CEO of ROX Medical, which developed a groundbreaking interventional vascular therapy for uncontrolled hypertension. Earlier in his career, Mike held senior leadership roles at Philips North America, where he was Vice President and Head of Sales for the Image Guided Therapy division. There, he played a key role in expanding the company’s interventional devices portfolio and led commercial due diligence for Philips’ $2B acquisition of Spectranetics in 2017, later overseeing the integration of a 500-person combined sales team.

Mike joined Philips following its acquisition of Volcano Corporation, where he had served as General Manager of the Phoenix Atherectomy division and Peripheral Sales Leader. His involvement with Volcano began with its acquisition of AtheroMed in 2014, where he was CEO at the time.

Alan Murray is an engineer, entrepreneur, and the co-founder and CEO of Conceivable Life Sciences, the biotech company behind AURA, the world’s first AI-powered automated IVF lab. Murray combines strategic leadership with deep technical expertise, driving the company’s reinvention of the IVF laboratory. As both CEO and architect of AURA, he has overseen the integration of artificial intelligence, robotics, advanced optics, and machine learning into a seamless platform designed to improve IVF outcomes while making the Nobel Prize–winning therapy more accessible and affordable. To date, Conceivable has raised $70M and will launch U.S. operations in 2026.

Before Conceivable, Murray co-founded and led TMRW Life Sciences, where he pioneered automated solutions for fertility storage and specimen management. His work there laid the groundwork for understanding how robotics and AI could transform the entire fertility ecosystem. Murray’s engineering philosophy centers on solving complex biological challenges through elegant technological solutions.

Over two decades, Murray and longtime partner Joshua Abram have co-founded and scaled
multiple category-defining ventures in technology, hospitality, and life sciences,, including Integral Ad Science (NASDAQ: IAS), Dstillery, and NeueHouse.

Dr. John Petrozza, a pioneer in minimally invasive gynecologic surgery, has spent his career pushing boundaries and advancing the field. From his early days as a resident, where he eagerly embraced laparoscopic techniques, to his role as Division Chief for Reproductive Endocrinology and Infertility, Dr. Petrozza, to his new role as Director of Business Development and Network Collaboration, he has been at the forefront of innovation.

Throughout his tenure at institutions like New England Medical Center/Tufts Medical School and Massachusetts General Hospital (MGH), Dr. Petrozza has consistently sought to expand surgical options and improve patient care. He has spearheaded initiatives such as the MGH Integrated Fibroid Program, demonstrating his commitment to interdisciplinary collaboration and patient-centric care.

With a passion for teaching, Dr. Petrozza has trained countless residents and fellows, instilling in them not only technical skills but also a profound appreciation for the art of reproductive surgery. He continues to advocate for the importance of surgical expertise within reproductive medicine, recognizing its pivotal role in patient outcomes and overall success.

As the field of gynecologic surgery evolves, Dr. Petrozza remains dedicated to fostering innovation, collaboration, and excellence. He looks forward to further contributing to the advancement of the specialty and invites others to join him on this journey.

Dr. Jared Robins has an undergraduate degree from Emory University and obtained his MD from the State University of New York Stony Brook. Following an OB/GYN residency at Albert Einstein College of Medicine he did his fellowship in Reproductive Endocrinology and Infertility at the University of Cincinnati. He also has an MBA from the Kellogg School of Management at Northwestern University. Dr. Robins is currently the CEO of the American Society for Reproductive Medicine. Prior to joining the ASRM, Dr. Robins has served as a faculty member at the University of Cincinnati, Brown University and Northwestern University, where he served as Chief of the Division of Reproductive Endocrinology and Infertility, and as Director of International Medicine. After leaving Northwestern, Dr. Robins was the Global Health Officer and Attending Physician at Vios Fertility Institute. In addition to his work in clinical care, Dr. Robins has been a prolific and well-funded researcher with numerous publications and grants. Dr. Robins has long been a member of ASRM and the Society for Reproductive Endocrinology and Infertility, where he served as Education Committee Chair and Secretary Treasurer. He has been an Editorial Board member for Fertility and Sterility and a Board Examiner for the American Board of Obstetrics and Gynecology.

David Sable MD is a physician, academic, and investor with a long career in reproductive endocrinology and life sciences. He earned his M.D. from the University of Pennsylvania in 1986, following a B.S. from the Wharton School in 1981. He did his residency in Obstetrics and Gynecology at New York Hospital-Cornell Medical Center, and a fellowship in Reproductive Endocrinology and Infertility at Brigham and Women’s Hospital in Boston. He is board-certified in Obstetrics and Gynecology (1994) and Reproductive Endocrinology (1997), and a past Fellow of both the American College of Obstetricians and Gynecologists and the American College of Surgeons.

Dr. Sable has held academic appointments at  Harvard Medical School and Columbia University, where he teaches Entrepreneurship in Biotechnology in the Department of Biological Sciences. He co-founded the Division of Reproductive Endocrinology at Saint Barnabas Medical Center, and embryo diagnostic company Reprogenetics, later acquired by Cooper Surgical. His management positions include healthcare analyst at Deutsche Bank and portfolio manager of the Special Situations Life Sciences Fund and the Special Situations Life Sciences Innovation Fund. He holds advisory and director positions for several biotech companies, including Hamilton Thorne Ltd., TMRW Life Sciences, Celmatix, AutoIVF Inc., Conceivable, and Evvy, and was a member of the board of directors of RESOLVE, which in 2023 awarded him the Barbara Eck Founders Award for lifetime achievement. He is also the recipient of the American Infertility Association’s Family Building Award and RÉSOLVE of New Jersey’s Zenith Award.

Denny Sakkas PhD has been involved in the field of In Vitro Fertilization (IVF) since the early 1980s, having gained his Ph. D. under the supervision of Prof. Alan Trounson at Monash University, in one of the leading Reproductive Research Units in the world. During this period, he was responsible for disseminating a number of innovations to laboratories around the world, which are used in routine IVF today. Included in this, was training many groups to perform micromanipulation and the initiation of blastocyst culture. He has subsequently headed his own Research Laboratories and been the Scientific/Laboratory Director of IVF units throughout Europe, the UK and the USA.

Dr. Sakkas has extensive experience in clinical IVF and reproductive research publishing in the field of sperm DNA damage, fertilization, early embryo development and male infertility. His research has more recently led the way in live imaging of human embryos, increasing our understanding of embryo metabolism and cell lineage.

Dr. Sakkas has been extensively funded in his research career and continues to work on innovations in the area of human and animal reproduction. These innovations span the spectrum of basic to translational research and commercial applications. He now currently serves as Chief Scientific Officer at Boston IVF / IVIRMA North America and as an Associate Professor at the Yale University School of Medicine.

Amarpreet Sawhney is the CEO of Instylla, Rejoni, Pramand, Sealonix, and Rayz Inc. In the past he was Chairman, President and CEO of Ocular Therapeutix, Inc. (NASDAQ: OCUL) a company focused on unmet needs in ophthalmic drug delivery and Chairman of Augmenix, Inc. a private company focused in improving outcomes of radiotherapy. Previously, he was Founder and CEO of Confluent Surgical (acquired by Covidien), a biosurgery company, the Chairman of MarketRx (acquired by Cognizant), a provider of pharmaceutical marketing and sales analytics and intelligence, technology founder of Focal, Inc. (acquired by Genzyme) and founder of Access Closure Inc. (acquired by Cardinal Health). He holds over 150 patents, which form the basis for several first-of-a-kind medical devices that have helped over 10 million patients worldwide. He has founded ten companies, which account for over 5,000 jobs created and over $5 billion in revenue to date. Dr. Sawhney helps foster entrepreneurship by mentoring young innovators and creating companies through Incept, a medical device incubator. He is a member of the board of directors of Axtria, Tulavi, StataDx, Pramand, Instylla, Rejoni, Sealonix, and Rayz, Inc. and is also a Founder of the last five companies. He is also on the advisory board of the MIT museum.

Dr. Sawhney is passionate about education, wildlife, and environmental causes, which he is involved in supporting through his family foundation. Dr. Sawhney has been recognized by several awards including being named the “Champions of Change” and “Outstanding American by Choice” awards by the Whitehouse, “Five most innovative Medical Device CEOs” by MassDevice, MassMedic best startup company award, Frost and Sullivan Product innovation award, MIT Global Indus Technovators Award, the E&Y regional entrepreneur of the year award, Mass High Tech All Star award, TiE Star award, the University of Texas Outstanding Young Engineering Graduate award, and the Indian Institute of Technology Delhi Distinguished Alumni award. Dr. Sawhney holds a Ph.D. and M.S. in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from IIT Delhi. He resides in Lexington, MA with his wife Deepika and two children Anhad (22) and Pria (20).

Dr. John Schnorr is a board certified Reproductive Endocrinologist, the Division Director of Reproductive Endocrinology at the Medical University of South Carolina and the Medical Director of Coastal Fertility Specialists, in Charleston, South Carolina. Dr. Schnorr did his undergraduate and medical school training at the University of Arizona in Tucson, Arizona. Following that, he did an Obstetrics and Gynecology residency at the University of Virginia and a 3 year Reproductive Endocrinology fellowship at the world renowned Jones Institute for Reproductive Medicine, a part of the Eastern Virginia Medical School.

Dr. Schnorr is the Founder of Coastal Fertility Specialists, the largest fertility center in South Carolina. Dr. Schnorr is also the founder and CEO of Cycle Clarity, an FDA approved clinical AI platform that uses a recurrent neural network to identify and measure follicles in an ovary ultrasound. Cycle Clarity decreases ultrasound time from 10 minutes to less than one minute and standardizes measurements across ultrasonographers. The platform provides AI enhanced downstream clinical and embryology data to optimize the time of oocyte retrieval and allow for a better understanding of upcoming clinical and embryology workflows.

Neel Shah, MD, MPP, FACOG, is Chief Medical Officer of Maven Clinic, the world’s largest digital clinic for women’s and family health, and a visiting scientist at Harvard Medical School. He oversees the design and delivery of Maven’s care model, serving 20 million people globally in all phases of life.

As a physician-scientist, Dr. Shah has written over 100 articles, and contributed to four books, including as senior author of Understanding Value-Based Healthcare (McGraw-Hill). He was also a term advisor to the Office of Research on Women’s Health at the National Institutes of Health.

Dr. Shah has been recognized with the Franklin Delano Roosevelt Humanitarian of the Year Award from the March of Dimes. He is featured in the 2023 Emmy-nominated film Aftershock, currently streaming on Hulu, and The Color of Care from the Smithsonian Channel and Executive Producer Oprah Winfrey. He serves on the boards of Neighborhood Villages, FamilyWell and Diana Health, and resides in Cambridge, MA.

Noor Siddiqui is the Founder and CEO of Orchid, a reproductive technology company. Prior to Orchid, Noor taught CS17si: Frontiers in Reproductive Technology at Stanford. She was an AI researcher at Stanford where she worked on applications of deep learning to genomics with Anshul Kundaje and computer vision applied to medical imaging with Sebastian Thrun. Noor has spoken internationally about her work at the intersection of technology and medicine at events like Milken’s Global Conference, WebSummit, and Kaiser Permanente’s Executive Leadership Summit. Her work has been covered by The Washington Post, Forbes, TechCrunch, among other outlets. Noor is also a recipient of the Thiel Fellowship, a grant program spawned by PayPal founder and Facebook board member Peter Thiel, supporting breakthrough technology companies. Noor earned her M.S. and B.S. in Computer Science from Stanford University.

Carlos Simon is a Professor of Obstetrics and Gynecology at the University of Valencia (Spain), Senior Lecturer PT, BIDMC Harvard University, USA, and President of the Carlos Simon Foundation, Spain.

His main clinical and scientific interest focuses on understanding human embryonic implantation, a critical process to the survival of the species, by considering the embryo, the maternal endometrium, and their cross-communication as crucial elements.

Among his major contributions is the discovery of a transcriptomic signature of endometrial receptivity (PMID: 20619403), later  validated by single-cell RNA-seq (PMID: 32929266), leading to  the patented ERA test to identify the personalized implantation window in infertile patients. He also identified a persistent decidualization defect in the endometrium of women with severe preeclampsia (PMC: 5635883), including its transcriptomic (PMC: 8553341) and multiomic signatures (PMID: 39775038).

Dr. Simón challenged the sterile uterus paradigm by identifying the endometrial microbiome (PMID: 27717732) and its role in pregnancy (PMC: 8725275). He also discovered and validated human  endometrial stem cells, paving the way for the first advanced cell therapy for Asherman’s Syndrome  (PMID: 27005892; EudraCT: 2016-003975-23).

For the human embryo, he developed a predictive model for aneuploidy in early embryos (PMID: 26151134), studied embryo mosaicism (PMCID: PMC8715143), and revealed the origin and clinical impact of cell-free embryonic DNA (PMID: 29471395; 32470458). His team derived and registered ten human embryonic stem cell lines for the Spanish National Stem Cell Bank (PMID: 20018958), establishing its Valencia Node in 2004. He also demonstrated that maternal microRNAs can modify the embryo’s transcriptome (PMID: 26395145), emphasizing embryo–endometrium cross-communication (PMID: 29390102).

Carlos Simón’s dedication to research excellence is evidenced by the publication of over 550 papers in peer-reviewed journals, which have received over 57,000 citations. He holds a Google Scholar H-index of 136, has edited 21 books in English, Spanish, and Portuguese, and has supervised 42 Ph.D. theses. His scientific achievements have been recognized with numerous awards, including the Rey Jaime I Medical Research Award in 2011, the ASRM Distinguished Research Award in 2016, the Lilly Foundation Biomedical Research Award in 2021, the Translational Medical Research Award from the Royal National Academy of Medicine of Spain in 2023 and the University–Society Award for the Transfer of Knowledge to Society. University of Valencia, Spain.

His commitment to excellence in clinical care is demonstrated by his instrumental role as a clinician and scientific director in establishing the clinical practice and research program of the IVI from 1994 to 2018 (www.ivirma.es). As an inventor and entrepreneur, his research has generated 17 patent applications that enabled the creation of Igenomix S.L. in 2011. He was a founder and chief science officer (CSO), leading a scientific/medical team of 120 Ph.D. students worldwide until Igenomix was acquired by Vitrolife in 2021, a biotech company devoted to precision medicine in reproductive health through advanced reproductive genetic diagnoses with an international footprint on all continents.

Since 2022, Carlos Simón has focused on philanthropy, channeling scientific advances in reproductive medicine toward social impact. His Foundation promotes research, education, and accessibility, aligned with values of determination, resilience, and integrity. This commitment has led to spin-offs that apply research in clinical settings:

• iPremom: Detects gestational diseases like early preeclampsia using non-invasive genetic testing.
• Asherman Therapy: Has developed a regenerative treatment for women affected by Asherman’s syndrome or atrophic endometrium.
• Premium Fertility: has successfully reinvented the embryo transfer procedure using an image-guided device and automated systems.

Evan is the Chief Executive Officer and a Co-Founder of Granata Bio, a US based biopharma company focused on women’s health and fertility. In his role, Evan is responsible for Granata Bio’s corporate, customer, and commercial strategies.

Before founding Granata Bio, Evan spent nine years at EMD Serono/Merck KgAA. Most recently, he served as the Marketing and Business Unit Head for the US Fertility/Fertility Technologies businesses. During this time, Evan spearheaded the creation of innovative programs aimed at expanding access to care for under-recognized patient groups. He has previously served on the corporate council of RESOLVE: The National Infertility Association and the American Society of Reproductive Medicine.

Evan is a graduate of Brown University and received an MBA in Healthcare Leadership from Yale University. He lives in the Boston area with his wife and two children. Outside of work, you can find Evan trail running, golfing, or hiking with his family.

Mr. Andrew Young brings more than 25+ years of clinical and industry leadership within MedTech, with a dedicated focus on training, education, and product adoption. He has deep expertise in professional and medical education, customer training programs, and product lifecycle management for medical devices, particularly in women’s health and reproductive medicine.

Mr. Young began his career at Cook Medical, where he served as Global Training Manager in OB/GYN, reproductive medicine, and tissue regeneration. In this role, he led a team responsible for designing and delivering customer success programs across the United States and international markets. He later advanced to Director of Strategic Alliances at VirtaMed, a leading high-fidelity simulation company, where he partnered with global medical societies and training organizations to elevate physician education through competency-based training, performance metrics, and skills mastery.

Most recently, Mr. Young served as Vice President of Education and Global Training at Femasys Inc., where he combined commercial leadership with professional education initiatives to accelerate product adoption and support market growth.

In addition to his corporate roles, Mr. Young is an active contributor to advancing access in women’s medicine. He currently serves on the ASRM Corporate Member Council and will assume the role of Chairman in 2025. He is also Co-Chair of ASRM Innovate, helping to shape the future of innovation and education in reproductive medicine.

Mr. Young holds a Bachelor of Science in Chemistry and Pre-Medical Studies, with additional undergraduate studies in Business.